Farmas USA

Eleuterio, con el Nasdaq has descubierto un nuevo mundo, eh??? :)))

SYN

Buenas.

Ya ha salido el report Q2 2015. Nada especial. No ha habido noticias salvo una que ahora comentaré. Hay una lista de catalizadores esperados.

http://www.prnewswire.com/news-releases/synthetic-biologics-reports-second-quarter-2015-financial-results-and-operational-highlights-300125848.html

Clinical Program Progress

Prevention of C. difficile infection and AAD – SYN-004:

-Expect topline data from first Phase 2a clinical trial (3Q 2015)
-Plan to initiate a Phase 2b proof-of-concept clinical trial (3Q 2015); anticipate enrolling approximately 370 patients at up to 75 global sites;
anticipate interim analysis of blinded data (2H 2015)
-Expect topline data from second Phase 2a clinical trial (2H 2015)

IBS-C – SYN-010:
-Expect topline data from first Phase 2 clinical trial (2H 2015)
-Plan to initiate second Phase 2 clinical trial (2H 2015); expect topline data (1H 2016)

TrimestaTM, an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS:

-Amended license and clinical trial agreements with University of California, Los Angeles (UCLA) in July 2015
-Informed by UCLA that MRI analyses are ongoing to evaluate changes in the brain that correlate with improvements seen in clinical outcomes
-Expect to report topline MRI data 30 days following receipt of this data from UCLA
-A separate UCLA-led, multi-center U.S. Phase 2 trial is underway focused exclusively on cognition utilizing Trimesta with a variety of currently
marketed MS drugs

Pertussis (whooping cough) – SYN-005:

-Seeking non-dilutive funding to support preclinical and clinical development (ongoing)

General and administrative expenses increased to $2.2 million and $3.9 million for the three and six months ended June 30, 2015, respectively, compared to $1.8 million and $2.9 million for the same periods in 2014. The increase of approximately 22% for the three months ended June 30, 2015 is primarily the result of increased employee costs and legal fees, offset by a decrease in stock-based compensation expense. The increase of approximately 34% for the six months ended June 30, 2015 is primarily the result of increased employee costs, legal fees and audit fees related to the additional procedures required under the accelerated filer status. Non-cash charges related to stock-based compensation were $335,000 and $915,000 for the three and six months ended June 30, 2015, respectively, compared to $645,000 and $899,000 for the same periods in 2014.

Research and development expenses increased to $7.5 million and $14.0 million for the three and six months ended June 30, 2015, respectively, compared to $2.8 million and $5.6 million for the same periods in 2014. The increases of approximately 165% and 152% for the three and six months ended June 30, 2015, respectively, are primarily the result of increased program costs associated with expanded clinical development, manufacturing and research activities for our microbiome-focused pipeline, including the Company's C. difficile and IBS-C programs. For the six months ended June 30, 2015, research and development expenses also include a $1.0 million expense for achieving the third milestone as set forth in the Asset Purchase Agreement with Prev ABR LLC, dated November 28, 2012, related to the C. difficile program. Prev ABR LLC exercised its option to receive the milestone payments in shares of Synthetic Biologics' common stock that were issued in April 2015. Non-cash charges related to stock-based compensation were $252,000 and $498,000 for the three and six months ended June 30, 2015, respectively, compared to $210,000 and $318,000 for the same periods in 2014.

Other expense was $3.9 million and $8.0 million for the three and six months ended June 30, 2015, respectively, compared to other income of $95,000 and $96,000 for the same periods in 2014. Other expense for the three and six months ended June 30, 2015 was primarily the result of a non-cash charge of $3.9 million and $8.0 million, respectively, related to the change in fair value of warrants due to the increase in the stock price from the previous quarter. There was no non-cash income or expense relating to fair value warrants for the three and six months ended June 30, 2014.

Cash and cash equivalents at June 30, 2015 was $4.8 million. Subsequent to the end of the second quarter, a public offering was completed for net proceeds of approximately $42.6 million. The strengthened balance sheet provides the Company with the resources to fund its clinical development programs.

SYN

Vaya ojo tienes ;)

Eso es gracias a vosotros.

Espérate, que habrá que ver a cómo abre, que igual abre a un +10%, o rojas, no se sabe. Pero vamos, que abre con un +10% y ya estoy haciendo clik.

OCAT

Entro en la página de Morningstar y ha desaparecido la línea del millón de acciones de Blackrock. Ni negativo, ni positivo ni nada. Pero el porcentaje de insiders está en 12,5 y 1,1% de institucionales. Un poco más que la última vez que lo miré. ¿Alguien lo entiende?

Un ojo en MEIP y otro en AVXL

Buenas tardes a todos,

Felicidades, Eleuterio... creo que te va a abrir con un +100% casi.. vas a doblar.. tremendo...

Mañana marcho de vacaciones, así que seguramente hasta final de mes no contactaré por aquí con vosotros...

Esta tarde terminaré de perfilar mis asuntos bursátiles...

AQXP

Vendidas a 19.50

Voy a por una copa ahora más tranquilo.